GSA Capital Partners LLP Purchases Shares of 555,944 MaxCyte, Inc. $MXCT

GSA Capital Partners LLP purchased a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 555,944 shares of the company’s stock, valued at approximately $684,000.

A number of other hedge funds also recently modified their holdings of the business. Renaissance Technologies LLC raised its position in MaxCyte by 153.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock worth $1,400,000 after purchasing an additional 1,206,300 shares during the last quarter. Brooklands Fund Management Ltd acquired a new position in MaxCyte during the 1st quarter worth about $1,538,000. Capricorn Fund Managers Ltd bought a new stake in shares of MaxCyte in the 1st quarter valued at about $5,760,000. Marquette Asset Management LLC bought a new stake in shares of MaxCyte in the 2nd quarter valued at about $351,000. Finally, BNP Paribas Financial Markets grew its position in shares of MaxCyte by 39.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after buying an additional 10,263 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MXCT. Weiss Ratings downgraded MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.00.

MaxCyte Stock Up 9.4%

MXCT stock opened at $1.39 on Thursday. The firm has a market cap of $143.46 million, a price-to-earnings ratio of -4.21 and a beta of 1.48. MaxCyte, Inc. has a 12-month low of $0.64 and a 12-month high of $1.86. The company’s fifty day simple moving average is $1.21 and its 200 day simple moving average is $0.99.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%.The firm had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.51 million. Research analysts expect that MaxCyte, Inc. will post -0.25 earnings per share for the current year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.